综述:乙型肝炎病毒感染的免疫预防与肝细胞癌预防
慢性HBV感染可导致肝硬化和肝细胞癌等高风险后果。本文更新了HBV相关HCC的分子与流行病学特征及抗病毒治疗获益,并评估了HBV疫苗的安全性、免疫原性和有效性。结论指出,尽管抗病毒治疗可减少但不能消除肝脏相关事件风险,而HBV疫苗接种是预防HBV及相关HCC的关键工具。
要点
- 慢性HBV感染显著增加肝硬化和肝细胞癌风险。
- 抗病毒治疗可降低但不能消除肝脏相关事件风险。
- HBV疫苗接种是预防HBV感染及相关HCC的关键优先工具。
核心结论
- 为实现2030年病毒性肝炎消除计划,HBV疫苗是实现世界卫生组织可持续发展目标的优先工具。
研究设计与样本
- 本文为综述,分析了近期发表的关于HBV复制、抗病毒治疗和疫苗接种的数据。
主要发现
- 肝细胞核内HBV复制周期涉及两个限制性步骤:形成超螺旋cccDNA微染色体和HBV DNA整合至宿主基因组,后者触发直接病毒性肝癌发生。
- 特异性抗病毒治疗可显著减少病毒复制,但仅降低而非消除肝脏相关事件风险,与HBV疫苗接种的预防作用形成对比。
临床怎么用
- 应将HBV疫苗接种作为预防HBV感染及相关肝细胞癌的优先策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic hepatitis B virus (HBV) infection results in a high risk of cirrhosis and its complications: cirrhosis decompensation, hepatocellular carcinoma (HCC, the fourth most common cause of cancer-related mortality worldwide), liver transplantation and death. It is now 40 years since development of the first plasmatic vaccine which has been proven to prevent (liver) cancer. AIMS: To update firstly the molecular and epidemiological aspects of HBV-related HCC and its natural history together with the benefits associated with viral suppression and secondly the safety, immunogenicity and efficacy of HBV vaccination. METHODS: Analysis of recent published data regarding HBV replication, anti-viral treatments and vaccination. RESULTS: The nuclear HBV replication cycle in the hepatocyte combines two limiting steps to achievement of HBV cure during chronic infection: the formation of a minichromosome, the supercoiled cccDNA, and host-genome integration of HBV DNA which triggers direct viral hepatocarcinogenesis. Even if specific anti-viral treatments significantly reduce viral replication, they decrease but do not cancel the risk of liver-related events in contrast with the prevention of HBV through HBV vaccination. CONCLUSIONS: To achieve the 2030 viral hepatitis elimination plan, the HBV vaccine is a priority tool for achieving the sustainable development goals of the World Health Organization.
引用
- Vallet-Pichard A, Pol S. Review article: immunisation against hepatitis B virus infection and the prevention of hepatocellular carcinoma. Aliment Pharmacol Ther. 2021. PMID: 33909923. doi:10.1111/apt.16356
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。